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Implications for practice and research  
 Healthcare professionals must review medications for appropriateness, 
efficacy and benefits to their patients and must communicate effectively with 
patients and relatives. 
 We need to re-examine and review drug use and prescribing practices to 
assert clinically and contextually appropriate care. However, qualitative 




Use of a variety of drugs (polypharmacy) is required to manage complex disease 
processes. At the end of life, the focus of ‘treatment’ changes from extending 
survival, to symptom management – therefore, aims of treatments change, requiring 
different pharmaceutical approaches1. A recent Delphi study used consensus 
opinion of 40 experts to label drugs as ‘often adequate’, ‘questionable’ and ‘often 
inadequate’ to prescribing practices in gerontology2. This expanded findings from the 
PIM list of potentially inappropriate medicines3, and developed a new grouping to 
inform clinical relevance. Thus, evaluation of actual practice and frequency in 
prescribing medicines across hospital and community settings at the end of life care 






This study4 presents a retrospective analysis of Swedish Health Registry data on 
prescribing in N58415 decedents aged over 75 who were assigned to ‘palliative care’ 
(defined as ‘cancer’, ‘organ failure’ or ‘prolonged dwindling’) during the last 3 months 
of life. 
Data included medications continued, medications initiated and those which were 
discontinued over 365 days prior to death. Prescriptions during the final three 
months were analysed to identify any prescribing of medicines deemed ‘often 
inadequate’ in palliative care settings3. Data were normalized to exclude patients 
with unpredictable fatal events (those with a sudden or unexpected dying trajectory) 
to assert clinical relevance. Patient demographics were linked to assert confounding 
variables such as age, gender, comorbidities, educational levels and illness 





Many older patients receive medicines which are of questionable benefit at the end 
of life. The most common are aimed at longer term outcomes, such as lipid lowering, 
calcium and iron supplementation and anti-dementia treatments. N18681 patients 
received continuing medication perceived of limited clinical benefit until the day they 
died, with N8180 having these medications initiated within the last three months of 
life. This was more prevalent for multimorbidity patients. Nursing home dwellers 
received less newly prescribed medicines. Inappropriate medications were 
discontinued more frequently in cancer patients.  
 
Commentary  
Pharmacovigilance is key to offering intelligence on prescribing practices across 
countries. This study is single country specific, so offers a snapshot of Swedish 
prescribing for elderly patients at the end of life. This study suggests clinicians need 
to consider ‘time-to-benefit’. Thus avoiding futile, ‘disease prevention’ drugs in 
palliative care. However, the discussion also identifies the requirement for clinicians 
to set mutual goals - to communicate with individual patients and their relatives, to 
ensure patients’ own health priorities are commensurate with prescribing practices. It 
also highlights the difficulties in discontinuation of medicines and the individual 
nuances of discussing these delicate subjects with patients and relatives at the end 
of life. Weighting prescription choices by predicting when a patient will die is fraught 
with potential issues. This is why the retrospective analysis of actual events offers an 
easier approach to assessing which drugs could have been prescribed, or indeed, 
discontinued.  
 
This study raises an important factor – that many medications are prescribed which 
offer limited clinical benefit. However, we need further qualitative studies to explore 
the potential impacts of discontinuation of treatments during the last few weeks / 
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